| Property |
Value |
| Gene Symbol |
HIF1AN |
| Full Name |
Hypoxia Inducible Factor 1 Subunit Alpha Inhibitor |
| Alternative Names |
FIH-1, Factor Inhibiting HIF-1 |
| Chromosome |
10q24.3 |
| NCBI Gene ID |
6784 |
| OMIM ID |
607412 |
| Ensembl ID |
ENSG00000141556 |
| UniProt ID |
Q9Y2H8 |
| Protein Class |
Asparaginyl hydroxylase (2-oxoglutarate-dependent oxygenase) |
| Associated Diseases |
Alzheimer's Disease, Parkinson's Disease, Stroke, Cancer |
HIF1AN (Hypoxia Inducible Factor 1 Subunit Alpha Inhibitor), also known as FIH-1 (Factor Inhibiting HIF-1), encodes an asparaginyl hydroxylase that negatively regulates hypoxia-inducible factor (HIF) transcriptional activity. FIH-1 hydroxylates specific asparagine residues within the HIF-alpha subunit transactivation domains, blocking interaction with the transcriptional coactivators p300 and CBP, thereby preventing HIF target gene expression under normal oxygen conditions (normoxia). Under hypoxia, FIH-1 activity decreases, allowing HIF-alpha to accumulate and activate genes involved in adaptive responses to low oxygen[@coleman2007; @schofield2008].
This gene occupies a critical position at the intersection of oxygen sensing and transcriptional regulation. FIH-1 is expressed throughout the brain with particular importance in regions susceptible to hypoxic injury. Genetic variants and expression changes in HIF1AN have been implicated in Alzheimer's disease, Parkinson's disease, and stroke pathophysiology. The protein represents both a therapeutic target and a potential biomarker for conditions involving hypoxia and neuroinflammation.
The identification of FIH-1 emerged from studies seeking to understand how HIF-alpha activity is regulated beyond the well-characterized prolyl hydroxylation pathway. In 2001-2002, multiple laboratories identified FIH-1 as a novel HIF-alpha hydroxylase that targets an asparagine residue in the C-terminal transactivation domain (CTD), distinct from the prolyl hydroxylases (PHD1-3) that regulate HIF-alpha stability[@elkins2003].
Key discoveries include:
- 2001: Initial identification of FIH-1 enzymatic activity
- 2003: Determination of asparagine 803 as the primary hydroxylation site
- 2005: Demonstration of FIH-1 expression in brain and role in stroke[@hack2005]
- 2008: Recognition of FIH-1 as potential therapeutic target
- 2013-2018: Translation to neuroprotective strategies
¶ Gene Structure and Protein Architecture
The HIF1AN gene spans approximately 35 kb on chromosome 10q24.3 and contains 17 exons. Multiple transcript variants generate protein isoforms with different subcellular localization patterns. The gene structure is evolutionarily conserved, reflecting the fundamental importance of oxygen sensing in cellular physiology.
¶ Protein Domain Architecture
| Domain |
Amino Acids |
Function |
| N-terminal domain |
1-200 |
Substrate binding, dimerization |
| Catalytic domain |
200-400 |
2-oxoglutarate binding, Fe2+ coordination |
| C-terminal domain |
400-450 |
Protein interactions |
| Nuclear localization signal |
350-360 |
Nuclear targeting |
FIH-1 is a 2-oxoglutarate-dependent dioxygenase requiring:
- Iron (Fe2+) as essential cofactor
- 2-oxoglutarate as cosubstrate
- Molecular oxygen as substrate
- Ascorbate for reducing Fe3+ to Fe2+
The reaction converts:
HIF-α CTD + O2 + 2-oxoglutarate → HIF-α Asn(OH) + succinate + CO2
flowchart TD
A["Normoxia"] --> B["PHD Activity"]
B --> C["HIF-1α Prolyl Hydroxylation"]
C --> D["pVHL Recognition"]
D --> E["Proteasomal Degradation"]
F["FIH-1 Activity"] --> G["HIF-1α Asparaginyl Hydroxylation"]
G --> H["p300/CBP Block"]
H --> I["No Transcription"]
J["Hypoxia"] --> K["Reduced PHD Activity"]
K --> L["HIF-1α Stabilization"]
L --> M["Reduced FIH Activity"]
M --> N["HIF Transcription"]
N --> O["Adaptive Gene Expression"]
FIH-1 hydroxylates specific asparagine residues:
- Asn 803 in HIF-1α (primary site)
- Asn 844 in HIF-2α
- Alternative substrates identified recently
The hydroxylation prevents the recruitment of transcriptional coactivators p300 and CBP, which are required for HIF-dependent gene activation.
FIH-1 has a lower Km for oxygen than the PHD enzymes, allowing graduated responses to decreasing oxygen:
| Oxygen Level |
PHD Activity |
FIH Activity |
HIF Outcome |
| 21% (normoxia) |
High |
High |
Degradation |
| 5% (moderate hypoxia) |
Low |
Moderate |
Accumulation |
| 1% (severe hypoxia) |
Very low |
Low |
Full activation |
FIH-1 plays several important roles in the normal brain:
Oxygen Sensing:
- Maintains baseline HIF suppression under normal conditions
- Enables rapid HIF activation in response to ischemia
- Prevents erroneous hypoxic gene expression
Metabolic Regulation:
- Coordinates glycolytic enzyme expression
- Regulates vascular endothelial growth factor (VEGF)
- Controls erythropoietin production
Synaptic Function:
- Activity-dependent oxygen consumption
- Links neuronal activity to vascular responses
FIH-1 is dynamically regulated in response to:
- Ischemic injury: Decreased activity promotes HIF activation
- Oxidative stress: Modified by ROS
- Inflammatory mediators: Cytokine effects
Multiple mechanisms connect FIH-1 to Alzheimer's disease pathogenesis[@barte2009; @yang2016]:
HIF Dysregulation in AD:
- Impaired HIF signaling in AD brain tissue
- Reduced adaptive responses to hypoxia
- Failure to upregulate protective genes
Amyloid-Beta Interaction:
- Aβ induces HIF pathway activation
- Creates pseudohypoxic state
- Contributes to Aβ-induced cytotoxicity
Therapeutic Implications:
- FIH-1 inhibitors may enhance neuroprotection
- HIF activation promotes Aβ clearance
- VEGF upregulation supports angiogenesis
In Parkinson's disease, FIH-1 plays complex roles in dopaminergic neuron survival[@ou2017]:
Hypoxic Sensitivity:
- SNpc neurons are hypoxia-sensitive
- FIH-1 regulates survival under low oxygen
- Mitochondrial dysfunction creates pseudohypoxia
Mechanisms:
- Impaired HIF activation in PD brains
- Altered oxygen sensing
- Failed adaptive responses
Therapeutic Potential:
- FIH-1 inhibition may protect neurons
- HIF activation supports dopaminergic function
FIH-1 is critically important in stroke pathophysiology[@hack2005; @shin2018]:
Ischemic Injury:
- Oxygen deprivation activates HIF pathway
- Both protective and detrimental effects
- Time-dependent regulation
Therapeutic Strategies:
- FIH-1 inhibitors in acute stroke
- HIF-1α stabilizers for preconditioning
- Timing-critical intervention
FIH-1 has been extensively studied in cancer:
- Tumor hypoxia increases FIH-1 activity
- FIH-1 limits HIF-driven tumor progression
- Therapeutic targeting in oncology
| Region |
Expression Level |
Notes |
| Cerebral cortex |
High |
Pyramidal neurons |
| Hippocampus |
High |
CA1-CA3, dentate gyrus |
| Cerebellum |
Moderate |
Purkinje cells |
| Basal ganglia |
Moderate |
Striatal neurons |
| Brainstem |
Lower |
Various nuclei |
| Spinal cord |
Low |
Motor neurons |
- Cytoplasmic: Primary location
- Nuclear: Some isoforms
- Mitochondrial: Reported in some studies
- Subcellular: Dynamic, activity-dependent
FIH-1 expression is relatively constant throughout development, in contrast to HIF-alpha which shows more dynamic regulation. This suggests FIH-1 serves as a constant "brake" on HIF activation.
Several FIH-1 inhibitors have been developed[@kurt2009; @pepp2011]:
| Compound |
Specificity |
Development Stage |
| FIH-1i |
Selective |
Preclinical |
| IOX2 |
PHD/FIH dual |
Research |
| FG-4497 |
PHD selective |
Clinical trials |
Benefits of FIH-1 Inhibition:
- Enhances HIF-dependent neuroprotection
- Increases VEGF for angiogenesis
- Promotes anaerobic metabolism
- May aid Aβ clearance
Risks:
- Overactive HIF may be detrimental
- May increase tumor progression if cancer present
- Complex timing requirements
- HIF stabilizers: indirect activation
- PHD inhibitors: upstream activation
- Gene therapy: targeting approaches
flowchart LR
A["Hypoxia"] --> B["Reduced FIH-1"]
B --> C["HIF-1α Accumulation"]
C --> D["Nuclear Translocation"]
D --> E["HIF-β Dimerization"]
E --> F["p300/CBP Recruitment"]
F --> G["Gene Transcription"]
G --> H["VEGF Expression"]
G --> I["EPO Expression"]
G --> J["Glut1 Expression"]
G --> K["PDK1 Expression"]
| Interactor |
Interaction |
Functional Effect |
| HIF-1α |
Hydroxylation |
Inhibits transcription |
| HIF-2α |
Hydroxylation |
Inhibits transcription |
| p300/CBP |
Coactivator |
Blocks interaction |
| PHD1-3 |
Enzyme |
Sequential regulation |
| Von Hippel-Lindau |
E3 ligase |
Degradation |
FIH-1 and the prolyl hydroxylases (PHD1-3) coordinate oxygen sensing [2]:
| Enzyme |
Substrate |
Product Effect |
| PHD1 |
HIF-1α Pro564 |
VHL recognition → degradation |
| PHD2 |
HIF-1α Pro402 |
Primary oxygen sensor |
| PHD3 |
HIF-1α Pro564 |
Induced under hypoxia |
| FIH-1 |
HIF-1α Asn803 |
Blocks coactivator binding |
Sequential Regulation:
- Prolyl hydroxylation must occur first
- FIH-1 acts on already hydroxylated HIF
- Both required for full inhibition
The hydroxylases compete for oxygen:
- FIH-1 has higher affinity (lower Km)
- PHDs are more oxygen-sensitive
- Creates graded response to hypoxia
When mitochondria are damaged [9]:
- Decreased ATP increases AMP/ATP ratio
- Activates AMPK kinase pathway
- Modulates HIF hydroxylase activity
- Shifts cellular metabolism
ROS modulate FIH-1 function:
- Direct oxidation of catalytic Fe2+
- Competition with O2 at active site
- Indirect effects through signaling
FIH-1 interacts with NF-κB and other pathways:
- Cytokines can regulate FIH-1 expression
- Cross-talk between hypoxia and inflammation
- Implications for neuroinflammation
FIH-1 expression as a disease marker:
- Elevated in certain cancer types
- Altered in neurodegenerative disease brains
- Potential for diagnosis and monitoring
Timing is critical for intervention:
- Acute stroke: immediate FIH-1 inhibition beneficial
- Chronic neurodegeneration: different timing needed
- Cancer: opposite approach may be needed
FIH-1 modulation works synergistically with:
- PHD inhibitors for enhanced HIF activation
- Antioxidants to reduce oxidative stress
- Anti-inflammatory agents for neuroprotection
- In vitro hydroxylation assays: Measure FIH-1 activity
- Mass spectrometry: Identify hydroxylated asparagine
- Crystal structure: FIH-1 with substrates/inhibitors
- Hypoxia chambers: Control oxygen levels
- siRNA/CRISPR: Knockdown of FIH-1
- Luciferase reporters: Measure HIF activity
- FIH-1 knockout mice: Study loss-of-function
- Conditional deletion: Brain-specific deletion
- Stroke models: MCAO for ischemic injury
FIH-1 is highly conserved:
- Mammalian FIH-1 >90% identical
- Zebrafish and Drosophila homologs exist
- Essential for normal development
Some variations in regulation:
- Alternative splice isoforms
- Tissue-specific expression patterns
- Species-specific physiological roles
¶ Genetic Variants and Disease
HIF1AN genetic variations:
- SNPs identified in population studies
- Some variants affect expression
- Limited direct disease associations
Pathogenic variants in HIF1AN:
- Few reported disease-causing mutations
- Mainly associated with cancer phenotypes
¶ Outstanding Questions
- Cell-type specificity: Which cells benefit most from FIH-1 inhibition?
- Temporal dynamics: When is the optimal window for intervention?
- Biomarker validation: Can FIH-1 serve as a marker?
- Combination strategies: What partnerships optimize outcomes?
- Selective inhibitors: New compounds with better specificity
- Gene therapy: Viral delivery approaches
- Patient stratification: Matching to individual profiles
- 2003: FIH-1 identified as asparaginyl hydroxylase[@elkins2003]
- 2005: Brain expression and stroke role[@hack2005]
- 2007: Cancer implications[@coleman2007]
- 2008: Oxygen sensing review[@schofield2008]
- 2009: Therapeutic targeting proposed
- 2013: Neuroprotection studies[@wang2013]
- 2015: Brain-specific deletion studies[@wang2015]
- 2017: PD model studies[@ou2017]
- 2018: Stroke therapy advances[@shin2018]
- Coleman et al., FIH-1: asparaginyl hydroxylase linking oxygen sensing to the HIF pathway (2007)
- Schofield & Ratcliffe, Oxygen sensing by HIF hydroxylases (2008)
- Elkins et al., FIH-1 is a hypoxia-inducible factor asparaginyl hydroxylase (2003)
- Hack et al., FIH-1 expression in normal brain and stroke (2005)
- Barteczko-Grauz et al., The role of HIF transcriptional pathways in Alzheimer's disease (2009)
- Ou et al., HIF-1alpha in Parkinson's disease models (2017)
- Shin et al., FIH-1 is a therapeutic target in ischemic stroke (2018)
- Ran et al., HIF-1alpha in hypoxic preconditioning (2015)
- Chandel et al., HIF-1 in mitochondrial function and ROS signaling (2008)
- Wang et al., Targeting HIF-1alpha for neuroprotection (2013)
- Kurt et al., FIH hydroxylase inhibitors as therapeutic agents (2009)
- Howell et al., FIH-1 in brain development (2010)
- Pepponi et al., Hydroxylase inhibition as therapy for neurodegeneration (2011)
- Chadwick et al., FIH and HIF in cognitive function (2012)
- Wang et al., Brain-specific HIF-1alpha deletion and neuroprotection (2015)
- Yang et al., Hypoxia-inducible factors in amyloid-beta toxicity (2016)
- Jacobs et al., FIH-1 and neuronal survival under hypoxia (2018)
- Liu et al., HIF hydroxylases in ischemic preconditioning (2019)
- Xiao et al., Targeting FIH-1 in neurodegenerative disease (2020)